Key advisor: FDA should hold diabetes drugs to different standard

Share this article:
In an opinion piece yesterday, the chair of the FDA advisory committee on Avandia recommended the agency change the way it evaluates experimental diabetes drugs.

“Without a regulatory sea change with regard to diabetes drugs, we are certain to be in the same position five years from now that we are in now,” wrote Clifford Rosen, MD, in an online “Perspective” piece for The New England Journal of Medicine. “We will again find ourselves in possession of a new wonder drug that is designed to treat a devastating chronic disease but that may do more harm than good.”

Rosen called the shifting away from surrogates like glycated hemoglobin levels, in favor of clinical outcomes, an “urgent need.” The agency took a similar step 20 years ago, he said, when it altered its end point for osteoporosis drugs from bone mineral density to fractures.

While glycemic control is the basis of therapeutic interventions in type 2 diabetes, it's a “relatively poor” surrogate for cardiovascular outcomes in type 2 diabetes, Rosen noted, accounting for only 5% to 15% of the variation in ischemic risk.

The July 30 advisory committee meeting bore that out. In one of the largest randomized trials of Avandia (rosiglitazone) studies evaluated as part of the meeting—A Diabetes Outcome Prevention Trial (ADOPT)—the percentage decrease in glycated hemoglobin was greater with rosiglitazone than with metformin or sulfonylureas, yet the risks of congestive heart failure and cardiovascular ischemia were higher, he pointed out.

The committee last month voted to keep the GlaxoSmithKline type 2 diabetes drug on the market but said its label should include strict warnings on use.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...